Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours (Q34409477)

2 August 2017

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours (English)

1 reference

2 August 2017

Arnold R

1

1 reference

2 August 2017

Trautmann ME

2

1 reference

2 August 2017

Creutzfeldt W

3

1 reference

2 August 2017

Benning R

4

1 reference

2 August 2017

Benning M

5

1 reference

2 August 2017

Neuhaus C

6

1 reference

2 August 2017

Jürgensen R

7

1 reference

2 August 2017

Stein K

8

1 reference

2 August 2017

Schäfer H

9

1 reference

2 August 2017

Bruns C

10

1 reference

2 August 2017

Dennler HJ

11

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 1996

1 reference

2 August 2017

1 reference

2 August 2017

38

1 reference

2 August 2017

430-438

1 reference

2 August 2017

3

1 reference

Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Revised classification of neuroendocrine tumors of the lung, pancreas and gut.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Carcinoids: the association of histologic growth pattern and survival

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Doxorubicin plus cisplatin in the treatment of apudomas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Prospective study of chemotherapy in patients with metastatic gastrinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Therapeutic embolisation of the hepatic artery: a review of 75 procedures

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Chemotherapy of endocrine malignancies: a review.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

The carcinoid syndrome: palliation by hepatic artery embolization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Endocrine pancreatic carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Treatment of Gastrointestinal Endocrine Tumours with Interferon-α and Octreotide

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Somatostatin and Analogues in the Treatment of Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

The somatostatin receptor in the GI tract

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1383075

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

6 July 2018

1 reference

12 December 2020

Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors

1 reference

12 December 2020

Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide

1 reference

12 December 2020

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera

1 reference

12 December 2020

Effects of Leukocyte Interferon on Clinical Symptoms and Hormone Levels in Patients with Mid-Gut Carcinoid Tumors and Carcinoid Syndrome

1 reference

12 December 2020

Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases

1 reference

12 December 2020

Regression of metastatic vipoma with somatostatin analogue SMS 201-995

1 reference

12 December 2020

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

1 reference

12 December 2020

Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)

1 reference

12 December 2020

Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor

1 reference

12 December 2020

Use of somatostatin analog in management of carcinoid syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1136/GUT.38.3.430

1 reference

2 August 2017

1 reference

2 August 2017

1 reference